| Identification | Back Directory | [Name]
RO 0437626 | [CAS]
134362-79-1 | [Synonyms]
RO 0437626
N-[(1R)-2-[[(1S,2R,3S)-1-(Cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]amino]-2-oxo-1-(4-thiazolylmethyl)ethyl]-1H-benzimidazole-2-carboxamide
1H-Benzimidazole-2-carboxamide, N-[(1R)-2-[[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]amino]-2-oxo-1-(4-thiazolylmethyl)ethyl]- | [Molecular Formula]
C27H35N5O4S | [MDL Number]
MFCD07363878 | [MOL File]
134362-79-1.mol | [Molecular Weight]
525.66 |
| Hazard Information | Back Directory | [Uses]
Ro 0437626 is a P2X1 purinergic receptor antagonist. | [Biological Activity]
Selective P2X 1 purinergic receptor antagonist (IC 50 = 3 μ M) that displays > 30-fold selectivity over P2X 2 , P2X 3 and P2X 2/3 receptors (IC 50 > 100 μ M). | [in vivo]
Ro 0437626 (1 and 10 μmol/kg; i.v.) causes a reduction in postinfusion isovolumetric contractions[3]. | Animal Model: | Female rat (urethane-anaesthetized)[3] | | Dosage: | 1 and 10 μmol/kg | | Administration: | I.v. | | Result: | Caused a reduction in postinfusion isovolumetric contractions.
|
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|